Clinical Trial Update: Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for teplizumab (MGA031) in moderate to severe psoriasis, a phase 1/2 safety study that was terminated with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• teplizumab (MGA031) (teplizumab)

Snippet

Sponsor: MacroGenics | Conditions: Psoriasis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2012-04-19